Ocular distribution and pharmacokinetics of lifitegrast formulations
AssigneeSarcode Bioscience Inc.
InventorsJou-Ku CHUNG, Elizabeth SPENCER, Matthew HUNT, Devin WELTY, Thomas MCCAULEY
Life of this patent
Estimating the term…
Abstract
The present invention provides lifitegrast formulations useful for the treatment of immune-related diseases of the ocular surface. The formulations and methods provided herein are particularly useful for treatment of ocular anterior segment tissues.
Claims22
A method of treating an immune-related disease of the ocular surface in a subject, the method comprising topically administering to the eye of the subject an effective amount of lifitegrast, or a pharmaceutically acceptable salt thereof, in a formulation that provides a lifitegrast maximum concentration (Cmax) of greater than about 5190 ng/mL in an ocular anterior segment tissue of the eye for a 1.75 mg dose of lifitegrast.
An ophthalmic formulation comprising lifitegrast, or a pharmaceutically acceptable salt thereof, wherein after topically administering to an eye of a subject, the formulation provides a lifitegrast maximum concentration (Cmax) of greater than about 5190 ng/mL in an ocular anterior segment tissue of the eye for a 1.75 mg dose of lifitegrast.
Dependencies are inferred from the claim text.